Market-Moving News for July 12th
$FAST
$IMMP
$ZAPP
RETAIL: Building Materials
Consumer Discretionary
Biotechnology: Pharmaceutical Preparations
Health Care
Save time and jump to the most important pieces.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 11/13/2024 | Neutral | UBS | ||
| 11/13/2024 | $120.00 → $135.00 | Neutral | UBS | |
| 10/7/2024 | $85.00 | Buy | BofA Securities | |
| 9/6/2024 | $72.00 | Equal-Weight | Morgan Stanley | |
| 5/17/2024 | $10.00 | Overweight | CapitalOne | |
| 9/15/2023 | $59.00 | Hold | HSBC Securities | |
| 8/3/2023 | $7.00 | Outperform | Robert W. Baird | |
| 7/13/2023 | $60.00 | Overweight → Equal-Weight | Stephens |
4 - FASTENAL CO (0000815556) (Issuer)
4 - FASTENAL CO (0000815556) (Issuer)
4 - FASTENAL CO (0000815556) (Issuer)
LONDON, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Zapp Electric Vehicles Group Limited (NASDAQ:ZAPP) ("Zapp EV" or the "Company"), owner of "Zapp", the British electric vehicle brand on a mission to revolutionise personal urban mobility, today announced it has entered into a turnkey engineering, procurement and construction (EPC) agreement with AIH Group to deliver its low-cost manufacturing reference site in the Bangkok Free Trade Zone, which is a 100 acre campus near Thailand's capital city offering a total of 220,000 square meters in manufacturing capacity. The new reference site will showcase Zapp's flexible manufacturing and Gen-2 sustainable assembly innovations, and completion is expected b
LONDON, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Zapp Electric Vehicles Group Limited (NASDAQ:ZAPP) ("Zapp EV" or the "Company"), owner of "Zapp", the British electric vehicle brand on a mission to revolutionise personal urban mobility, today announced the appointment of David McIntyre as Chief Operating Officer ("COO") effective immediately. David, who previously served as Zapp's Chief Commercial Officer, brings to this newly created role an extensive background in scaling operations for luxury and performance automotive brands as Zapp prepares to expand operations to additional countries in Europe and Asia. As COO, David will be responsible for managing supply chain logistics, overseeing con
Fastenal Company (NASDAQ:FAST) (the 'Company' or 'Fastenal') has appointed Jeff Watts, a 28-year Company veteran with deep global sales experience, to the position of President and Chief Sales Officer, effective August 1, 2024. Mr. Watts will assume the President role from Dan Florness, who will be voluntarily vacating the President position on the effective date. Mr. Florness will continue to serve as Fastenal's CEO and as a member of its Board of Directors. In addition to serving as President, Mr. Watts will continue in his role as the Company's Chief Sales Officer (CSO), a position he has held since May 2023. As CSO, his responsibilities include establishing priorities, setting goals,
UBS resumed coverage of Fastenal with a rating of Neutral
UBS resumed coverage of Fastenal with a rating of Neutral and set a new price target of $135.00 from $120.00 previously
BofA Securities initiated coverage of Fastenal with a rating of Buy and set a new price target of $85.00
Fastenal Company (NASDAQ:FAST) (collectively referred to as 'Fastenal' or by terms such as 'we', 'our', or 'us'), a leader in the wholesale distribution of industrial and construction supplies, today announced its financial results for the quarter ended September 30, 2024. Except for share and per share information, or as otherwise noted below, dollar amounts are stated in millions. Throughout this document, percentage and dollar calculations, which are based on non-rounded dollar values, may not be able to be recalculated using the dollar values included in this document due to the rounding of those dollar values. References to daily sales rate (DSR) change may reflect either growth (posit
Fastenal Company (NASDAQ:FAST) (collectively referred to as 'Fastenal' or by terms such as 'we', 'our', or 'us') reported its board of directors declared a dividend of $0.39 per share to be paid in cash on November 22, 2024 to shareholders of record at the close of business on October 25, 2024. Except for share and per share information, dollar amounts are stated in millions. We began paying annual dividends in 1991, semi-annual dividends in 2003, and then expanded to quarterly dividends in 2011. In addition to these regular dividend payments, we have previously paid special one-time dividends in December 2008, December 2012, December 2020, and December 2023. Our board of directors current
Fastenal Company (NASDAQ:FAST) (collectively referred to as 'Fastenal' or by terms such as 'we', 'our', or 'us') announced the date and time for its conference call to review 2024 third quarter results, as well as current operations. The conference call will be broadcast live over the Internet on Friday, October 11, 2024 at 9:00 a.m. central time. To access the call, please visit the following Web address: https://investor.fastenal.com/events.cfm Our conference call presentation (which includes information, supplemental to that contained in our earnings announcement, regarding results for the quarter) will be available at 6:00 a.m., central time, on the day of the conference call. To acc
SC 13G/A - FASTENAL CO (0000815556) (Subject)
SC 13G/A - IMMUTEP Ltd (0001506184) (Subject)
SC 13G/A - FASTENAL CO (0000815556) (Subject)
6-K - IMMUTEP Ltd (0001506184) (Filer)
144 - FASTENAL CO (0000815556) (Subject)
144 - FASTENAL CO (0000815556) (Subject)
4 - FASTENAL CO (0000815556) (Issuer)
4 - FASTENAL CO (0000815556) (Issuer)
Media Release Mature data in patients with a minimum follow-up of 22 months (N=21) shows excellent results, well above historical controls and exceeding expectations: Median Overall Survival is 32.9 months, with median Progression Free Survival reaching 12.7 months, and a 24-month Overall Survival rate of 81.0% Data from all evaluable patients to date (N=40) demonstrates significant improvement of Overall Response Rate compared to historical controlsSafety continues to be favourable with no new safety signalsINSIGHT-003, which is nearing completion of enrolment, evaluates efti with the most widely used immunotherapy-chemo combination today in a similar population to upcoming TACTI-004 Phase
Media Release Efti in combination with pembrolizumab and radiotherapy demonstrates significant efficacy in the neoadjuvant setting in patients with soft tissue sarcomaOver three-fold increase in tumour hyalinization, the primary endpoint of the study and an important predictor of overall survival, as compared to historical results from radiotherapy alone SYDNEY, AUSTRALIA, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces the presentation of new data from EFTISARC-NEO, a Phase II investigator-initiated tria
Positive feedback received from US FDA regarding the planned TACTI-004 Phase III in first-line non-small cell lung cancer successfully concluding regulatory preparations for the trial designEfti in combination with MSD's KEYTRUDA® reports positive efficacy and favourable safety in first-line head and neck cancer in TACTI-003 Phase IIb trialFirst participant successfully dosed in the first-in-human Phase I trial of IMP761, a novel LAG-3 agonist antibody designed to treat autoimmune diseasesImmutep added to the S&P ASX300 Index, recognising its considerable growth and enhancing market visibilityImmutep has a strong aggregate cash, cash equivalent and term deposit position of A$172.3 million as
Final discussion with the FDA, successfully concluding the regulatory preparations for the TACTI-004 Phase III trial design to evaluate efti in combination with KEYTRUDA® (pembrolizumab), MSD's anti-PD-1 therapy, and standard chemotherapy in first-line non-small cell lung cancerTACTI-004 registrational trial will enrol ~750 patients regardless of PD-L1 expression in order to address the entire 1L NSCLC market eligible for anti-PD-1 therapySYDNEY, AUSTRALIA, July 22, 2024 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces that
Study expected to enrol first participants during Q3 CY2024 SYDNEY, AUSTRALIA, July 17, 2024 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces it has received regulatory clearance from the ethics and competent authority in the Netherlands to initiate the first-in-human Phase I study of IMP761.IMP761 is the world's first therapeutic LAG-3 agonist antibody and as such is uniquely positioned in the treatment landscape for autoimmune diseases. The immune checkpoint LAG-3 has been identified as a promising target for agonist immu